Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 26, 2011. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,148,000 ordinary shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,296 pence per share; lowest price paid was 1,262 pence per share.
- Treasury Shares Held: 502,996,816 shares (9.01% of total issued share capital).
- Treasury Shares (Including Unsettled): 503,996,816 shares (9.92% of current total voting rights).
- Shares in Issue: 5,078,996,810 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the purchase and subsequent cancellation of 1,148,000 shares. This action increased the proportion of shares held in Treasury relative to total voting rights to 9.92% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,078,996,810) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 1,148,000 share cancellation on the total issued share capital.
- Note that the company holds approximately 9.92% of its own voting rights in Treasury, including unsettled transactions.